Absorption Systems?and its?ACF Bioservicessubsidiary announced that they have been certified by the European Medicines and Healthcare products Regulatory Agency (MHRA).
Cambrex?has entered into a definitive agreement to acquire?Avista Pharma Solutions?for roughly $252 million. Avista is a portfolio company of Ampersand Capital Partners.
These potency assays range from relatively simple protocols to more complex and elaborate designs that determine the mechanism of action of a gene therapy product.
Synthetic Genomics, Inc. and Advaxis, Inc. have completed development and deployment of the first cGMP synthetic biology facility for the production of synthetic DNA constructs.